T.Rx Capital is a venture capital firm launched in 2025 to invest at the intersection of technology and biology. With deep roots in biotech innovation and access to one of the largest academic-commercial ecosystems in the world, T.Rx Capital was created to back companies developing transformative biomedical and tech-enabled solutions.
The firm focuses on early-stage companies working in biotech, techbio, and tech-enabled services. Within drug development, it prioritizes next-generation modalities such as cell and gene therapies, radiopharmaceuticals, and novel biologics. Beyond therapeutics, the firm invests in AI-driven drug discovery platforms and digital tools designed to accelerate clinical development and commercialization.
T.Rx Capital announced the close of its debut fund in September 2025, raising $77.5 million. The fund targets 10 to 15 portfolio companies globally, with a strategy to invest between $5 million and $10 million per company. The firm intends to lead or co-lead early-stage rounds from formation through Series B, taking active roles in creation, scale, and governance. The fund’s backers include family offices and a group of influential limited partners, among them founders of Polaris Partners, Third Rock Ventures, and Arch Venture Partners. The raise comes at a time of renewed momentum in the biotech capital markets, with T.Rx positioning itself to capture the next wave of scientific and technological breakthroughs.
Leadership
T.Rx is led by Michael Langer, Corey McCann, and Kwesi Frimpong-Boateng. Langer brings experience from investment roles at Polaris and Boston Seed Capital as well as from founding Old Silver VC. McCann contributes operating expertise as the former CEO of Pear Therapeutics, while Frimpong-Boateng adds business development experience from Eli Lilly. The firm is supported by a scientific advisory board chaired by Bob Langer and including Mark Levin of Third Rock Ventures, Freda Lewis-Hall, former Chief Medical Officer of Pfizer, and Al Sandrock, CEO of Voyager Therapeutics and former Biogen executive.
Investment Strategy
T.Rx Capital employs a hands-on strategy that blends deep operator experience with access to one of the richest global biotech ecosystems. It leverages the extensive alumni network of Bob Langer’s lab at MIT, which includes more than 1,000 leaders across academia and industry, to source unique deal flow. The firm positions itself not just as a capital provider but as an active partner in shaping company formation, scaling scientific platforms, and guiding governance as startups progress to later stages.
Notable Investments
As a newly launched fund, T.Rx Capital has not yet disclosed specific portfolio investments. Its pipeline is expected to reflect its focus on techbio startups, next-generation therapeutic modalities, and AI-enabled discovery companies.
Notable Exits
As the fund is newly raised, no exits have been reported to date.
Other
The firm’s name reflects its dual mission: “Rx” for medicine and “T” for technology. With its scientific and investment pedigree, T.Rx aims to fill the gap between traditional biotech investing and the growing field of technology-enabled life sciences.
